The development of CAR-T therapies faces challenges such as limited efficacy, toxicities, antigen escape, and reduced persistence of CAR-T cells. In the previous article,… Read More »Advancing CAR-T Therapy: CAR-T Challenges and Horizon (Part 2)
Discover the innovation of CAR-T therapies, designed to specifically target cancer cells, showing remarkable efficacy against leukemias and lymphomas. This first blog of a… Read More »Advancing CAR-T Therapy: Breakthroughs and Diverse Approaches (Part 1)
Tumor xenograft models are valuable tools for evaluating drug efficacy and safety. Among these models, Patient-Derived Xenografts (PDX) and Cell Line-Derived Xenografts (CDX) are… Read More »How to use Cell line Derived Xenograft (CDX) and Patient Derived Xenograft (PDX) humanized mouse models
Believe it or not, every white mouse is unique in its own way! Despite seeming identical to the untrained eye, each mouse carries its… Read More »The Intricacies of Mouse Individuality: Uniqueness in Every White Mouse
As many as 95% oncology drug candidates fail clinical trials — and that’s despite them showing promising results in preclinical studies. One of biggest… Read More »Sourcing your humanized mouse models: top tips for success
As our understanding of oncology continues to grow, so does the opportunity to develop novel treatments that more effectively treat a range of cancers.… Read More »How the right preclinical model supports immuno-oncology treatment development
The landscape of HIV (Human Immunodeficiency Virus) research has been an evolving one, with remarkable strides made over the past decades. However, the quest… Read More »Mice are not men and yet… Challenging the Status Quo: Why CD34+ Humanized Mice Are Dethroning Non-Human Primates in HIV Research
Novel immuno-oncology treatments show great promise in treating cancers. But with approximately 95% of oncological drugs that have shown efficacy in preclinical studies failing… Read More »Maximize your immuno-oncology study potential with the right mouse model
TransCure bioServices’ CEO Patrick Nef shares his thoughts on what the changes will mean for drug development In December 2022, the U.S. House of… Read More »The FDA removes animal testing requirement for drug candidates
The drug development process is long and expensive, taking up to 15 years and costing $1.1 billion for the average drug. Shorter timelines are… Read More »How does your preclinical mouse model affect drug development timelines?
